Research programme: muscular dystrophy gene therapy - Tapestry Pharmaceuticals

Drug Profile

Research programme: muscular dystrophy gene therapy - Tapestry Pharmaceuticals

Alternative Names: DMD gene therapy - NaPro BioTherapeutics; Muscular dystrophy gene therapy - NaPro BioTherapeutics

Latest Information Update: 10 Aug 2005

Price : $50

At a glance

  • Originator Tapestry Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Genetic transcription inhibitors; Genetic transcription stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Muscular dystrophies

Most Recent Events

  • 10 Aug 2005 Discontinued - Preclinical for Muscular dystrophy in USA (unspecified route)
  • 11 May 2004 Napro Biotherapeutics is now called Tapestry Pharmaceuticals
  • 11 Dec 2003 Preclinical trials in Muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top